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Abstract
Background: Cancer genomes display characteristic patterns of chromosomal imbalances, often with diagnostic and 
prognostic relevance. Therefore assays for genome-wide copy number screening and simultaneous detection of copy 
number alterations in specific chromosomal regions are of increasing importance in the diagnostic work-up of tumors.
Results: We tested the performance of Multiplex Amplicon Quantification, a newly developed low-cost, closed-tube 
and high-throughput PCR-based technique for detection of copy number alterations in regions with prognostic 
relevance for neuroblastoma. Comparison with array CGH and the established Multiplex Ligation-dependent Probe 
Amplification method on 52 neuroblastoma tumors showed that Multiplex Amplicon Quantification can reliably 
detect the important genomic aberrations.
Conclusion: Multiplex Amplicon Quantification is a low-cost and high-throughput PCR-based technique that can 
reliably detect copy number alterations in regions with prognostic relevance for neuroblastoma.
Background
Recurrent alterations in DNA copy number are a com-
mon feature in many cancers and typically target biologi-
cal pathways and processes that contribute to cancer 
pathogenesis. The diagnostic and prognostic relevance of 
these chromosomal imbalances (gains, losses and ampli-
fications) has been demonstrated in an increasing num-
ber of tumor entities [1]. For the detection of unbalanced 
chromosomal aberrations different profiling platforms 
are commercially available. Array CGH is a commonly 
applied high-resolution genome-wide screening method 
for research and diagnostic purposes [2] but currently 
remains relatively expensive and labor-intensive. Alterna-
tively, PCR-based methods for the simultaneous detec-
tion of copy number changes in selected chromosomal 
regions such as Multiplex Ligation-dependent Probe 
Amplification (MLPA) [3] are well established and suited 
to be applied on a routine basis [4].
In this study, we evaluated the performance of a new 
method for relative quantification of specific DNA 
sequences in routine laboratory practice, called Multiplex 
Amplicon Quantification (MAQ) [5-9]. For this purpose, 
a MAQ assay was specifically designed for neuroblastoma 
(NB), the most common solid extra-cranial pediatric 
malignancy [10]. This is a good model for MAQ valida-
tion as intensive research of genomic imbalances has 
revealed insights into the clinical and biological heteroge-
neity of this tumor [11]. More specifically, prognostic rel-
evant, critical regions of loss and gain in NB have been 
delineated, the most important being 1p deletion, MYCN 
amplification, 3p deletion, 11q deletion and 17q gain [12-
16]. Of further importance, new therapeutic protocols 
based on the presence or absence of these segmental 
abnormalities are in progress [16]. The MAQ-NB assay 
allows the detection of CNAs in the prognostic relevant 
regions in NB. In this study, MAQ results were compared 
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to copy number changes detected with MLPA on a series 
of 52 NB for which detailed array CGH profiles were 
available.
Methods
Neuroblastoma tumor samples and cell lines
A representative series of NB tumor samples was col-
lected prior to therapy (34 cases from the Ghent Univer-
sity Hospital, Belgium and 14 from the Medical School of 
Valencia, Spain) (see Additional File 1). Of these 48 NB 
samples, 17 samples present with only numerical and 31 
with segmental aberrations (sometimes in a numerical 
background). MYCN amplification occurs in 19 cases. 
Additionally, 4 NB cell lines with segmental aberrations 
of which 3 with MYCN amplification were included in 
this study (NB-19, GI-CI-N, SJ-NB-10, LAN-6). DNA was 
isolated from NB tumors, cell lines and control samples 
using the Qiagen DNA isolation kit (QIAgen) according 
to the manufacturer's instructions.
Multiplex Ligation Probe Amplification (MLPA)
For MLPA analysis, the SALSA NB kits P251 (targeting 
chromosome 1, 3 and 11) and P252 (targeting chromo-
some 2 and 17) (MRC-Holland) were used to investigate 
DNA aberrations in specific chromosome regions of 
interest for NB [17]. The third NB kit P253, targeting 
chromosome 4, 7, 9, 12 and 14, was not used for this 
study. In the case of MYCN amplified NB samples, a 
MYCN silencing solution was added. Target regions are 
indicated in Figure 1. 100 ng of tumor DNA was used for 
each MLPA reaction. In each experiment three control 
samples were analysed, allowing accurate normalisation, 
including an EBV cell line, constitutional blood from a 
healthy individual and human genomic DNA (Roche). 
MLPA was performed according to the manufacturer's 
protocol with minor adaptations in the PCR step. Briefly, 
PCR was performed using 10 Pl of the ligase-product and 
40 Pl of PCR-mix containing 2 Pl of SALSA primers, 2 Pl 
SALSA enzyme dilution buffer, 4 Pl SALSA PCR buffer 
and 0.5 Pl polymerase, diluted in HPLC water, prepared 
on ice.
Multiplex Amplicon Quantification (MAQ)
For MAQ analysis, three kits were designed, MAQ1, 
MAQ2 and MAQ3 as described in the results section. 50 
ng of tumor DNA was needed for each reaction of the 
MAQ analysis. For accurate normalisation, two control 
samples were included in each experiment, i.e. constitu-
tional DNA from a healthy individual and human 
genomic DNA (Roche). After addition of 10 Pl of PCR 
mix and 0.075 Pl of Taq polymerase, samples were heated 
in a thermocycler with a heated lid (PTC200, Bio-Rad) for 
2 minutes at 98°C for activation of the polymerase. Fur-
ther PCR conditions required 22 cycles, including dena-
turation at 95°C for 45 seconds, annealing at 60°C for 45 
seconds and extension for 2 minutes at 68°C. This was 
followed by a final extension step at 72°C for 10 minutes.
Capillary electrophoresis and data analysis
For both MLPA and MAQ, resulting PCR products were 
analysed by capillary electrophoresis. A mixture of 8.5 Pl 
formamide (HiDi, Applied Biosystems) and 0.5 Pl internal 
lane standard (Rox500, Applied Biosystems) was pre-
pared and 1 Pl of the PCR-product was added. After a 2 
minute denaturation-step at 95°C, the samples were ana-
lyzed on the ABI3130XL (Applied Biosystems) capillary 
electrophoresis system. The raw data generated by frag-
ment analysis were analysed in a specially designed soft-
ware program Coffalyser [18] and MAQ-S [5] for MLPA 
and MAQ, respectively. Both programs were designed to 
calculate and visualise the normalised peak area or dos-
age quotient which reflects copy number of each target 
amplicon. Dosage Quotients (DQ) are calculated using 
the reference amplicons (in regions with low occurrence 
of aberrations) and the control samples (without genomic 
aberrations). For one reference amplicon (RefA) and one 
control sample (ctr), the DQ of a target amplicon (TarA) 
in sample (s) is as follows: DQ = [TarA(s)/RefA(s)]/
[TarA(ctr)/RefA(ctr)]. Based on the data of all reference 
amplicons and control samples, a final DQ is calculated 
as the mean of the individual DQs and the standard devi-
ation of the DQs (visualized as error bars) is a measure of 
stability.
Scoring rules for MLPA and MAQ
Optimal scoring thresholds were applied for MLPA and 
MAQ. For MLPA scoring (linear scale) we applied the fol-
lowing criteria. Regions were scored as segmental dele-
tions or gains if the dosage quotients of at least 2 
consecutive loci is 0.25 below or above 1, respectively 
[19]or when more than 75% of the probes show a 
decrease or increase of at least 0.15, respectively. When 
no segmental aberrations were detected in the tumor, the 
presence of numerical changes was evaluated. Regions 
are scored as whole chromosomal losses or gains if at 
least 75% of the dosage quotients of both p and q arm 
have a value below or above 1, respectively and more than 
half of the dosage quotients show an decrease or a 
increase of at least 0.1. MYCN amplification is scored if 
the 2 dosage quotients for the MYCN locus increase with 
at least 3. For MAQ scoring (linear scale) we applied the 
following criteria. Regions were scored as segmental dele-
tions or gains if the dosage quotients of at least 2 consec-
utive loci is 0.2 below or above 1, respectively (according 
to the manufacturer's instructions). When no segmental 
aberrations were detected in the tumor, the presence of 
numerical changes was evaluated. Regions are scored as 
whole chromosomal losses or gains if at least 75% of the 
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dosage quotients of both p and q arm have a value below 
or above 1, respectively and more than half of the dosage 
quotients show an decrease or an increase of at least 0.1. 
For scoring of MYCN amplification the 3 dosage quo-
tients for the MYCN locus should increase with at least 3.
Array Comparative Genomic Hybridisation (array CGH)
Samples were profiled on an in-house developed 1 Mb 
resolution BAC array as previously described [13] (18 
samples) or on a custom designed 44K array (Agilent 
Technologies) (34 samples) enriched for critical regions 
in NB (e.g. 1p, 2p, 3p, 11q, 17). Utilizing random prime 
labeling (BioPrime ArrayCGH Genomic Labeling System, 
Invitrogen), 400 ng of tumor and control DNA (DNA 
from an EBV cell line or male control DNA, Promega) 
was labeled with Cy3 and Cy5 dyes (GE healthcare). Fur-
ther processing was then performed according to the 
manufacturer's instructions (Agilent Technologies). 
Slides were scanned using an Agilent scanner (Agilent 
Technologies), features were extracted using the feature 
extraction v10.1.1.1 software program and further pro-
cessed with an in-house developed visualisation software 
program arrayCGHbase [20,21]. Array CGH profiles 
were evaluated manually after application of the circular 
binary segmentation (CBS) algorithm, which is an algo-
rithm to dissect genomic array data into regions of equal 
copy number by applying a maximal t-statistic with a per-
mutation reference distribution to determine the change-
points [22]. Gains are indicated in green (CBS value > 
0.3); losses are indicated in red (CBS value < -0.3).
Results
Construction of the MAQ neuroblastoma assay
The MAQ technique consists of the quantification of flu-
orescently labelled test and control amplicons, obtained 
by a single multiplex PCR (mPCR) amplification. As a 
first step in the construction of the MAQ neuroblastoma 
assay, primers were designed in the critical regions of loss 
(1p, 3p and 11q) and gain (2p -more specifically the 
MYCN locus- and 17q) for NB and their respective oppo-
site chromosome arm [12,13,15]. Specialised software [5] 
was used for the development of PCR primer sets within 
the chromosome regions of interest with a very high mul-
tiplexing degree, targeting up to 40 sequences each with a 
unique length. In this way, the NB-MAQ assay was cre-
ated consisting of three kits. MAQ1 contains a total of 21 
primer pairs with target regions on chromosome 3 and 17 
and MAQ2 contains 19 primer pairs targeting chromo-
some 1 and 11. For the detection of MYCN (2p) status, a 
separate kit (MAQ3) was designed, containing 9 primer 
pairs for chromosome 2. This was necessary since the 
high levels of (MYCN) amplification interfered with reli-
able analysis of other amplicons generated in the multi-
plex PCR. Additionally, each kit includes 8 or 9 primer 
sets, covering chromosomal regions that show the lowest 
frequency of copy number changes in NB (chromosome 
5q, 13q, 21q, 22q) and serve as reference sequences used 
Figure 1 Karyo view indicating regions covered by MAQ (1) and MLPA amplicons (2).
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for accurate normalisation. These regions were carefully 
selected through screening of the chromosomal status on 
array CGH profiles of 1000 NB cases (De Preter et al., in 
preparation). The MAQ target regions are indicated in 
Figure 1. More detailed information on the target regions 
of the MAQ kits can be found in Additional File 2.
Evaluation of the MAQ assay by comparison with MLPA and 
array CGH
The performance of the MAQ assay for the detection of 
CNAs in prognostic relevant regions was evaluated by 
comparing results of 48 NB tumor samples and 4 NB cell 
lines with corresponding MLPA and array CGH profiles 
(Additional File 3). For this analysis, each sample was 
screened once and scoring was applied as described in 
the Methods section. Based on array CGH results (Addi-
tional File 4), 2 groups were defined. One group consists 
of 17 tumor samples which presented exclusively with 
numerical aberrations (whole chromosome gains and 
losses), whereas the second group of 35 samples was 
characterised by the presence of segmental aberrations, 
sometimes in a numerical background (15/35). Two NB 
tumor profiles representative for each subgroup are 
shown in Figure 2, illustrating high concordance between 
array CGH, MLPA and MAQ results.
Performance of MLPA and MAQ for the detection of 
aberrations in each of the prognostic relevant regions is 
summarised in Table 1. The area under the curve (AUC) 
of the receiver operating curve (ROC) was used as a mea-
sure for accuracy, summarizing the sensitivity and speci-
ficity for a given test. High-quality tests with almost 
perfect performance will have an AUC approaching 
100%. ROC curves are shown in Additional File 5. Array 
CGH was used as golden standard for these analyses. For 
the subset of tumors with segmental aberrations, perfor-
mance for detecting 1p, MYCN, 3p, 11q and 17q status 
was very high for both techniques with average AUC of 
97.2% and 98.9% for MLPA and MAQ, respectively. The 
false positive rate for MLPA and MAQ was 4.7% and 
0.9%, respectively. For MLPA, no false negatives were 
detected while for MAQ one false negative was detected 
at chromosome 1p (false negative rate of 1.1%). It should 
be noted that the reference amplicons in this individual 
were all located in regions with a low level loss, therefore 
the lost 1p region appeared as normal.
For the 17 cases presenting with only numerical aberra-
tions, performance was evaluated for whole chromosome 
changes. Overall, performance rates were less optimal for 
these tumors with average AUC of 78.5% and 82.5% for 
MLPA and MAQ, respectively. When looking more into 
detail, the AUC remains high for chromosome 17 for 
both techniques (AUC is 0.941), demonstrating that high 
level gains are easily detected. While lower performance 
is seen for chromosome 1, 2, 3 and 11. As well for array 
CGH as for MLPA and MAQ, detection of whole chro-
mosome gains and losses in near-triploid tumors is chal-
lenging. Nevertheless, these aberrations can be detected 
rather unambiguously with array CGH due to the high 
amount of oligos used on these platforms (as can be seen 
in Figure 2B). This problem is inherent to characteristics 
in NB tumors with numerical aneuploidy where many 
chromosomes are implicated, including those used as ref-
erence for normalisation. No false positives were detected 
with MAQ and the false positive rate for MLPA was 
11.7%, while the false negative rate was 23.5% and 24.1%, 
respectively. Importantly, for these near-triploid tumors 
the only clinically relevant question is whether any seg-
mental aberrations are detected and this is not the case 
when MAQ is used.
Furthermore, repeatability of MAQ measurements was 
tested by performing Bland-Altman analysis [23]. From 
this method the coefficient of repeatability was derived 
by calculating the average difference ± 1.96 standard 
deviation of the difference. MAQ1 measurements of 6 
samples (4 tumors with segmental aberrations and 2 with 
numerical aberrations) were found reliably repeatable. 
The coefficient of repeatability was 0.121 for the tumors 
with segmental and 0.0987 for the tumors with numerical 
imbalances and therefore fall within the threshold bound-
aries used in the scoring procedure.
Discussion
MAQ is a new PCR-based method that allows to deter-
mine the copy number status of multiple loci in a single 
assay. Similar to MLPA, this technique fills the gap 
between more expensive genome-wide screening assays 
and cheaper methods that only provide information on a 
single locus. We validated MAQ in a model for NB as an 
alternative for MLPA, using array CGH data as a refer-
ence point. This study shows that MAQ is a robust and 
repeatable method for detection of prognostic relevant 
CNAs in recurrently affected regions in NB tumors and 
cell lines. For all investigated samples, MYCN amplifica-
tion status, which is one of the strongest prognostic 
parameters, was accurately determined. In addition, 
MAQ reliably differentiates between tumors with seg-
mental aberrations (which are correlated to poor progno-
sis) and tumors with numerical aberrations (correlated to 
good prognosis) [15]. For the detection of segmental 
gains and losses of one or more copies in 35 NB samples, 
performance was very high even when measured in a 
numerical background (Table 1). Of notice, the few dis-
crepancies measured (both for MLPA and MAQ) could 
represent very small aberrations, which we anticipate to 
be very rare. The validity of such putative small aberra-
tions might be examined by MLPA or MAQ assays 
enriched for probes in this region, ultra-high resolution 
arrays with dense coverage in this region or even next 
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generation sequencing but this lies beyond the scope of 
our study. Detection of whole chromosome imbalances in 
near-triploid tumors is more challenging for both array 
CGH and MLPA and MAQ. In general the presence of 
multiple gains and losses in these tumors hampers nor-
malisation [24]. In our study, 16 out of 17 tumors with 
numerical aberrations (and even in 15/35 with segmen-
tal), one or more reference chromosomes show CNAs, 
thus further complicating accurate normalisation for 
MAQ. In the case of NB, the pattern of these tumors is 
clearly recognisable [13]. In addition, for prognostic pur-
poses, it is not of importance to know which chromo-
somes are numerically aberrant but whether a distinction 
can be made between tumors with segmental and numer-
Figure 2 Two representative examples of aCGH, MLPA and MAQ NB tumor profiles A. NB cell line SJNB-10 with segmental aberrations, including 
1p deletion, MYCN amplification, 3p deletion, 17q gain. B. NB tumor with numerical aberrations including whole chromosome 1, 2 and 17 gain, and 
whole chromosome 3 and 11 loss. Gray = normal; Red = loss; Green = gain (according to scoring thresholds). Horizontal bars in array profiles indicate 
CBS values. Red and green cross marks point at CBS values above or below 0.3 or -0.3, respectively. In Figure 2B all crosses indicate known copy number 
variations. Error bars of each dosage quotient (DQ) are based on the standard deviation after summarizing the DQ values using different reference 
amplicons and 3 (MLPA) or 2 (MAQ) control samples.
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ical aberrations. Importantly, not a single false positive 
segmental aberration was detected by MAQ in near-trip-
loid tumors with only numerical aberrations. In addition, 
whole chromosome 17 gain detection which is one of the 
typical characteristics of these tumors, was almost per-
fectly detected, thus allowing assignment of these tumors 
to the prognostic favorable category.
Conclusion
We demonstrated that the newly developed MAQ 
method can be used as a valuable diagnostic tool for reli-
able detection of copy number changes with prognostic 
relevance in NB. Overall, PCR-based techniques harbor 
advantages in comparison to array CGH such as reduced 
expenses and sample-handling while maintaining high 
performance. Moreover the equipment needed, i.e. a 
thermal cycler and a capillary electrophoresis system, is 
present in the majority of molecular biology laboratories 
performing routine diagnostics. As MAQ allows to mea-
sure copy number status of as much as 40 targets in one 
reaction, this is sufficient for many routine tests for which 
only a well defined and specific number of imbalances 
needs to be analysed. When comparing MLPA to MAQ, 
the latter method may have certain advantages (see Table 
2). It requires less DNA, reduced handling, experiment 
time and costs, while it occurs in a single closed-tube 
reaction, maximally limiting contamination problems. 
Moreover, this test appears slightly more robust in our 
hands. At present, guidelines for the diagnostic work-up 
of NB recommend two independent molecular methods 
for the assessment of genetic alterations in NB [16]. In 
this context MAQ can be very well suited as complemen-
tary method to array CGH or FISH.
List of abbreviations
(AUC): Area under the curve; (CBS): Circulary Binary 
Segmentation; (MAQ): Multiplex Amplicon Quantifica-
tion; (MLPA): Multiplex ligation-dependent probe ampli-
fication; (mPCR): Multiplex PCR; (NPV): Negative 
predictive value; (NB): Neuroblastoma; (PPV): Positive 
predictive value; (ROC): Receiver Operating Characteris-
tic.
Table 1: Performance of MLPA and MAQ
Chromosome 1p MYCN status Chromosome 3p Chromosome 11q Chromosome 17q
Segmental (n = 35) MLPA MAQ MLPA MAQ MLPA MAQ MLPA MAQ MLPA MAQ
AUC 94.4% 97.1% 100.0% 100.0% 94.3% 100.0% 97.1% 97.1% 100.0% 100.0%
Sensitivity 100.0% 94.4% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Specificity 88.9% 100.0% 100.0% 100.0% 92.0% 100.0% 95.5% 95.5% 100.0% 100.0%
PPV 90.0% 100.0% 100.0% 100.0% 83.3% 100.0% 92.9% 92.9% 100.0% 100.0%
NPV 100.0% 94.4% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
95% Confidence Interval AUC(MLPA): 94%-100% 95% Confidence Interval AUC(MAQ): 97%-100%
Chromosome 1 Chromosome 2 Chromosome 3 Chromosome 11 Chromosome 17
Numerical (n = 17) MLPA MAQ MLPA MAQ MLPA MAQ MLPA MAQ MLPA MAQ
AUC 76.5% 88.2% 92.3% 76.9% 58.8% 76.5% 70.6% 76.5% 94.1% 94.1%
Sensitivity 77.8% 77.8% 90.0% 70.0% 46.2% 69.2% 71.4% 71.4% 94.1% 94.1%
Specificity 75.0% 100.0% 100.0% 100.0% 100.0% 100.0% 66.7% 100.0% 100.0% 100.0%
PPV 77.8% 100.0% 100.0% 100.0% 100.0% 100.0% 90.9% 100.0% 100.0% 100.0%
NPV 75.0% 80.0% 75.0% 50.0% 36.4% 50.0% 33.3% 42.9% 100.0% 100.0%
95% Confidence Interval AUC(MLPA): 60%-97% 95% Confidence Interval AUC(MAQ): 72%-93%
Performance in tumors with segmental (35) and numerical (17) aberrations for the recurrent NB copy number changes at chromosome 1(p), 
2 (MYCN status), 3(p), 11(q) and 17(q). This evaluation includes area under curve (AUC), positive predictive value (PPV) and negative predictive 
value (NPV).
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Additional file 1 Patient data on 48 neuroblastoma tumors. Patient 
data on 48 neuroblastoma tumors including INSS stage, age at diagnosis, 
MYCN amplification status and survival status.
Additional file 2 Overview primer pools of MAQ1 (A), MAQ2 (B) and 
MAQ3 (C). Overview of primer pools used for MAQ1 (A), MAQ2 (B) and 
MAQ3 (C) including details of chromosomal location
Additional file 3 Scoring table of 48 tumors and 4 cell lines with seg-
mental (A) and numerical (B) aberrations. Scoring table of 31 tumors 
and 4 cell lines with segmental aberrations (A). Thirty-five tumors display 
with segmental aberrations. Scoring was performed at the regions of inter-
est at 1p, MYCN amplification (MNA) status, 3p, 11q and 17q. Scoring table 
of 17 tumors with exclusively numerical aberrations (B). Seventeen tumors 
display with only numerical aberrations. Scoring was performed at the 
regions of interest at for both chromosome arms for chromosome 1, 2, 3, 11 
and 17. Red indicates clear loss, light red indicates a loss where the thresh-
old is barely reached, light green indicates a gain where the threshold is 
barely reached, green indicates clear gain. Black indicates that there was no 
data obtained.
Additional file 4 Array CGH results of 48 NB samples and 4 cell lines. 
Array CGH results of 48 NB samples and 4 cell lines that were profiled on 44 
K oligoarray or BAC array
Additional file 5 Overview of ROC curves of MLPA and MAQ assays 
versus array CGH. Overview of ROC curves of MLPA and MAQ assays ver-
sus array CGH at 1p, 2p, 3p, 11q and 17q for tumors with segmental and 
numerical aberrations.
Table 2: Overview of parameters important for aCGH, MLPA and MAQ
Array CGH (44 K) MLPA MAQ
Number of sequences 
investigated per 
experiment
44000 DNA sequences up to 45 DNA sequences (5 
control probes)
up to 40 DNA sequences (9-10 
control amplicons)
Number of reactions 1 2 3
Input DNA 150-400 ng DNA/reaction 100-200 ng DNA/reaction 50 ng DNA/reaction
Throughput intermediate high very high
Experiment time results within 72 h results within 24 h results within 6 h
Hands-on time high medium low
Detection of numerical 
aberrations
+ +/- +/-
Material oven, array scanner, software thermocycler and capillary 
electophoresis system
thermocycler and capillary 
electophoresis system
Consumables*
(patient and reference 
samples included)
205 €
(1 control sample included)
88 €
(3 control** samples included)
66 €
(2 control** samples included)
*For the price calculation we envisioned an experiment in which only 1 NB sample is screened which is reasonable as NB is a very infrequent 
tumor (approximately 20 new cases in Belgium every year)
**The MLPA protocol recommends to use at least 3 control samples while 2 control samples are sufficient for MAQ according to the 
manufacturers
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